Breaking Tolerance to Unresponsiveness to Immunotherapy by Natural Killer Cells

Texte du rabat

Breaking Tolerance to Unresponsiveness to Immunotherapy by Natural Killer Cells presents chapters by leaders in translational natural killer cell research and bridges the gap between clinical need and basic science by presenting state-of-the-art knowledge on innate immunity and the challenges associated with translating it to practical adoptive immunotherapies. New approaches, such as the genetic engineering of NK cells and their combination with checkpoint blockade therapies are discussed among other potential interventions to improve natural killer cell functionality against targets. In addition, challenges, such as the difficulty in genetically modifying NK cells or a poor understanding of their effect on checkpoint inhibition are included.The book is a key reference and go-to resource for researchers and clinicians who want to understand the current limitations associated with bringing natural killer cell-based immunotherapies to the clinic.

Contenu

1. Expanding the persistence of adoptively-transferred NK cells: Cytokine priming and epigenetic imprinting
   
   2. Targeting purinergic signaling to improve natural killer cells immunotherapy of solid tumors
   3. Genetic engineering of CD19-targeted chimeric antigen-receptor NK cells derived from cord blood as clinical treatment for immunotherapy of B cell lymphoma
   4. New sources of functionally-mature NK cells: peripheral blood-derived induced pluripotent stem cells
   5. The contribution of natural killer cells to immunotherapy with PD-1/PD-L1 checkpoint blockade
   6. Molecular checkpoints controlling NK cell activation and anti-tumor immunity
   7. Exploiting hypoxia's role in driving functional responses by IL-15-primed NK cells to target solid tumors
   8. Metabolic reprogramming and the role of mTOR in driving NK cell anti-tumor immunity
   9. Allo-reactive NK cells in immunotherapy of lung cancer: a clinical perspective
   10. Control of tumor metastasis by NK cells
   11. Challenges and opportunities with NK cells in the clinical treatment of acute myeloid leukemia